Introduction
The emergence of influenza A pandemic (H1N1) 2009 virus, presumably from swine to humans, has spread globally since April 2009 [1] . This emergence prompted the World Health Organization (WHO) to declare a pandemic of this virus on June 11, 2009. Although most cases of infection are mild or asymptomatic, 15,174 fatal cases were reported to the WHO as of February 5, 2010 [2] .
Therapeutic options are presently limited to two neuraminidase (NA) inhibitors, oseltamivir and zanamivir,
Materials and Methods
From July 1 to November 30, 2009, 96 respiratory specimens from cases positive for influenza A/H1N1 RT-PCR were tested for oseltamivir resistance. The testing was done by nucleotide sequencing of the NA gene by pyrosequencing using CDC primers Uni-sw-N1-B-F780, Uni-sw-N1-B-R1237-biot and Uni-sw-N1-BF804seq to detect the presence of the H275Y mutation as in the WHO/CD pyrosequencing protocol [5] .
Results
Of the 96 positive influenza A/H1N1 isolates, we detected 1 A/H1N1 strain which we designated as A/UAE/ A01/2009(H1N1) that was resistant to oseltamivir. The isolate was recovered from an 8-year-old child who had received a prophylactic course of treatment with oseltamivir because 2 of his siblings had confirmed H1N1 infection. Three days after finishing his prophylactic treatment, the child reported to the hospital with a characteristic clinical picture. Sequences indicated that the NA genes in the nasopharyngeal aspirate isolate contained an H ] Y mutation at the NA 274 (H3 numbering, 275 in H1 numbering) residue (Genbank accession No. CY053412). No other NA mutations known to be associated with oseltamivir resistance were observed.
Discussion
Resistance to NA inhibitors among seasonal strains of human influenza viruses (A/H1N1, A/H3N2 and B) has been rare until recently. Oseltamivir resistance associated with the NA 274Y genotype was also observed in human infections with avian influenza A virus (H5N1) [6] .
Oseltamivir-resistant influenza A/H1N1 (2009) virus had been reported from Denmark, Japan and Hong Kong [7] . In all cases, however, the patients had a history of prior treatment with oseltamivir as in our patient which we attributed to the possibility of a drug-induced mutation. Development of resistance after oseltamivir treat- fig. 1 ) .
We would like to point out that adequate knowledge of this virus is still limited, and characterization of transmission properties of this resistant variant in in vitro and in vivo models is needed. Moreover, pandemic (H1N1) 2009 virus should be closely monitored for emergence of resistant variants. It is imperative that systematic antiviral sensitivity testing should be undertaken to detect rapidly the emergence of antiviral resistance in both seasonal and pandemic influenza A/H1N1 virus.
